Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL HOME INFUSION THERAPY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL HOME INFUSION THERAPY MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL HOME INFUSION THERAPY MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 INDUSTRY INSIGHTS
7 REGULATORY FRAMWORK
8 IMPACT OF COVID-19 PANDEMIC ON THE MARKET
8.1 PRICE IMPACT
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC DECISION FOR MANUFACTURER/SERVICE PROVIDER
8.5 CONCLUSION
9 GLOBAL HOME INFUSION THERAPY MARKET, BY PRODUCT
9.1 OVERVIEW
9.2 INFUSION PUMPS
9.2.1 BY FUNCTION
9.2.1.1. SPECIALTY PUMPS
9.2.1.1.1. PATIENT CONTROLLED ANALGESICS (PCA) AND VOLUMETRIC PUMPS
9.2.1.1.2. ENTERAL INFUSION PUMPS
9.2.1.1.3. INSULIN INFUSION PUMPS
9.2.1.2. TRADITIONAL INFUSION PUMPS
9.2.1.2.1. SYRINGE INFUSION PUMPS
9.2.1.2.2. DISPOSABLE PUMPS
9.2.1.2.3. LARGE VOLUME PUMPS
9.2.1.2.4. ELASTOMERIC PUMPS
9.2.1.3. SMART PUMPS
9.2.2 BY MOBILITY
9.2.2.1. AMBULATORY INFUSION PUMPS
9.2.2.2. STATIONARY INFUSION PUMPS
9.2.3 BY INFUSION CHANNELS
9.2.3.1. 2 INFUSION CHANNELS
9.2.3.2. 4 INFUSION CHANNELS
9.2.3.3. MULTIPLE INFUSION CHANNELS
9.2.3.4. OTHERS
9.3 INTRAVENOUS SETS
9.3.1 FILTERED IV SETS
9.3.2 VENTED IV SETS
9.3.3 NON-VENTED IV SETS
9.3.4 GRAVITY TUBING
9.4 IV CANNULAS
9.4.1 BY TYPE
9.4.1.1. PEN-LIKE MODEL
9.4.1.2. WINGS MODEL
9.4.1.3. INJECTION PORT MODEL
9.4.1.4. Y-TYPE MODEL
9.4.2 IV THERAPY
9.4.2.1. CENTRAL IV CANNULA
9.4.2.2. MID-LINE IV CANNULA
9.4.2.3. PERIPHERAL IV CANNULA
9.5 NEEDLELESS CONNECTORS
9.5.1 NEUTRAL FLUID DISPLACEMENT
9.5.2 POSITIVE FLUID DISPLACEMENT
9.5.3 NEGATIVE FLUID DISPLACEMENT
10 GLOBAL HOME INFUSION THERAPY MARKET, BY AGE GROUP
10.1 OVERVIEW
10.2 PEDIATRICS
10.3 ADULTS
11 GLOBAL HOME INFUSION THERAPY MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 ANTI-INFECTIVE
11.3 ENDOCRINOLOGY
11.3.1 DIABETES
11.3.2 OTHERS
11.4 HYDRATION THERAPY
11.4.1 ATHLETES
11.4.2 OTHERS
11.5 CHEMOTHERAPY
11.6 ENTERAL NUTRITION
11.7 PARENTERAL NUTRITION
11.8 SPECIALTY PHARMACEUTICALS
11.9 IMMUNOGLOBULIN THERAPY
11.1 OTHERS
12 GLOBAL HOME INFUSION THERAPY MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDERS
12.3 RETAILS SALES
12.4 THIRD PARTY DISTRIBUTION
13 GLOBAL HOME INFUSION THERAPY MARKET, BY COUNTRY
13.1 GLOBAL HOME INFUSION THERAPY MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
13.1.1 NORTH AMERICA
13.1.1.1. U.S.
13.1.1.2. CANADA
13.1.1.3. MEXICO
13.1.2 EUROPE
13.1.2.1. GERMANY
13.1.2.2. FRANCE
13.1.2.3. U.K.
13.1.2.4. ITALY
13.1.2.5. SPAIN
13.1.2.6. RUSSIA
13.1.2.7. TURKEY
13.1.2.8. BELGIUM
13.1.2.9. NETHERLANDS
13.1.2.10. SWITZERLAND
13.1.2.11. REST OF EUROPE
13.1.3 ASIA-PACIFIC
13.1.3.1. JAPAN
13.1.3.2. CHINA
13.1.3.3. SOUTH KOREA
13.1.3.4. INDIA
13.1.3.5. AUSTRALIA
13.1.3.6. SINGAPORE
13.1.3.7. THAILAND
13.1.3.8. MALAYSIA
13.1.3.9. INDONESIA
13.1.3.10. PHILIPPINES
13.1.3.11. REST OF ASIA-PACIFIC
13.1.4 SOUTH AMERICA
13.1.4.1. BRAZIL
13.1.4.2. ARGENTINA
13.1.4.3. REST OF SOUTH AMERICA
13.1.5 MIDDLE EAST AND AFRICA
13.1.5.1. SOUTH AFRICA
13.1.5.2. SAUDI ARABIA
13.1.5.3. UAE
13.1.5.4. EGYPT
13.1.5.5. ISRAEL
13.1.5.6. REST OF MIDDLE EAST AND AFRICA
13.1.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
14 GLOBAL HOME INFUSION THERAPY MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: GLOBAL
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
14.3 COMPANY SHARE ANALYSIS: EUROPE
14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
14.5 MERGERS & ACQUISITIONS
14.6 NEW PRODUCT DEVELOPMENT & APPROVALS
14.7 EXPANSIONS
14.8 REGULATORY CHANGES
14.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
15 GLOBAL HOME INFUSION THERAPY MARKET, SWOT AND DBR ANALYSIS
16 GLOBAL HOME INFUSION THERAPY MARKET, COMPANY PROFILE
16.1 CAESAREA MEDICAL ELECTRONICS
16.1.1 COMPANY OVERVIEW
16.1.2 REVENUE ANALYSIS
16.1.3 GEOGRAPHIC PRESENCE
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 BD
16.2.1 COMPANY OVERVIEW
16.2.2 REVENUE ANALYSIS
16.2.3 GEOGRAPHIC PRESENCE
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 BAXTER
16.3.1 COMPANY OVERVIEW
16.3.2 REVENUE ANALYSIS
16.3.3 GEOGRAPHIC PRESENCE
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 B. BRAUN MELSUNGEN AG
16.4.1 COMPANY OVERVIEW
16.4.2 REVENUE ANALYSIS
16.4.3 GEOGRAPHIC PRESENCE
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENTS
16.5 FRESENIUS KABI AG
16.5.1 COMPANY OVERVIEW
16.5.2 REVENUE ANALYSIS
16.5.3 GEOGRAPHIC PRESENCE
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENTS
16.6 ICU MEDICAL
16.6.1 COMPANY OVERVIEW
16.6.2 REVENUE ANALYSIS
16.6.3 GEOGRAPHIC PRESENCE
16.6.4 PRODUCT PORTFOLIO
16.6.5 RECENT DEVELOPMENTS
16.7 JMS CO.LTD.
16.7.1 COMPANY OVERVIEW
16.7.2 REVENUE ANALYSIS
16.7.3 GEOGRAPHIC PRESENCE
16.7.4 PRODUCT PORTFOLIO
16.7.5 RECENT DEVELOPMENTS
16.8 SMITHS MEDICAL
16.8.1 COMPANY OVERVIEW
16.8.2 REVENUE ANALYSIS
16.8.3 GEOGRAPHIC PRESENCE
16.8.4 PRODUCT PORTFOLIO
16.8.5 RECENT DEVELOPMENTS
16.9 TERUMO CORPORATION
16.9.1 COMPANY OVERVIEW
16.9.2 REVENUE ANALYSIS
16.9.3 GEOGRAPHIC PRESENCE
16.9.4 PRODUCT PORTFOLIO
16.9.5 RECENT DEVELOPMENTS
16.1 COSMED SRL
16.10.1 COMPANY OVERVIEW
16.10.2 REVENUE ANALYSIS
16.10.3 GEOGRAPHIC PRESENCE
16.10.4 PRODUCT PORTFOLIO
16.10.5 RECENT DEVELOPMENTS
16.11 OPTUM, INC.
16.11.1 COMPANY OVERVIEW
16.11.2 REVENUE ANALYSIS
16.11.3 GEOGRAPHIC PRESENCE
16.11.4 PRODUCT PORTFOLIO
16.11.5 RECENT DEVELOPMENTS
16.12 INFUSYSTEM
16.12.1 COMPANY OVERVIEW
16.12.2 REVENUE ANALYSIS
16.12.3 GEOGRAPHIC PRESENCE
16.12.4 PRODUCT PORTFOLIO
16.12.5 RECENT DEVELOPMENTS
16.13 OPTION CARE HEALTH INC.
16.13.1 COMPANY OVERVIEW
16.13.2 REVENUE ANALYSIS
16.13.3 GEOGRAPHIC PRESENCE
16.13.4 PRODUCT PORTFOLIO
16.13.5 RECENT DEVELOPMENTS
16.14 MOOG INC.
16.14.1 COMPANY OVERVIEW
16.14.2 REVENUE ANALYSIS
16.14.3 GEOGRAPHIC PRESENCE
16.14.4 PRODUCT PORTFOLIO
16.14.5 RECENT DEVELOPMENTS
16.15 CARECENTRIX, INC.
16.15.1 COMPANY OVERVIEW
16.15.2 REVENUE ANALYSIS
16.15.3 GEOGRAPHIC PRESENCE
16.15.4 PRODUCT PORTFOLIO
16.15.5 RECENT DEVELOPMENTS
16.16 LINCARE HOLDINGS INC.
16.16.1 COMPANY OVERVIEW
16.16.2 REVENUE ANALYSIS
16.16.3 GEOGRAPHIC PRESENCE
16.16.4 PRODUCT PORTFOLIO
16.16.5 RECENT DEVELOPMENTS
16.17 PROMPTCARE RESPIRATORY
16.17.1 COMPANY OVERVIEW
16.17.2 REVENUE ANALYSIS
16.17.3 GEOGRAPHIC PRESENCE
16.17.4 PRODUCT PORTFOLIO
16.17.5 RECENT DEVELOPMENTS
16.18 NIPRO
16.18.1 COMPANY OVERVIEW
16.18.2 REVENUE ANALYSIS
16.18.3 GEOGRAPHIC PRESENCE
16.18.4 PRODUCT PORTFOLIO
16.18.5 RECENT DEVELOPMENTS
16.19 NEWIV MEDICAL, INC
16.19.1 COMPANY OVERVIEW
16.19.2 REVENUE ANALYSIS
16.19.3 GEOGRAPHIC PRESENCE
16.19.4 PRODUCT PORTFOLIO
16.19.5 RECENT DEVELOPMENTS
16.2 ELI LILLY AND COMPANY
16.20.1 COMPANY OVERVIEW
16.20.2 REVENUE ANALYSIS
16.20.3 GEOGRAPHIC PRESENCE
16.20.4 PRODUCT PORTFOLIO
16.20.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST RELATED REPORTS
17 CONCLUSION
18 QUESTIONNAIRE
19 ABOUT DATA BRIDGE MARKET RESEARCH
